- Home
- LGMK vs TOVX Comparison
LGMK vs TOVX Comparison
Compare LGMK & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGMK
- TOVX
- Stock Information
- Founded
- LGMK 2011
- TOVX 2001
- Country
- LGMK United States
- TOVX United States
- Employees
- LGMK N/A
- TOVX N/A
- Industry
- LGMK Industrial Specialties
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- LGMK Health Care
- TOVX Health Care
- Exchange
- LGMK Nasdaq
- TOVX Nasdaq
- Market Cap
- LGMK 3.1M
- TOVX 3.5M
- IPO Year
- LGMK N/A
- TOVX 2006
- Fundamental
- Price
- LGMK $1.58
- TOVX $1.18
- Analyst Decision
- LGMK
- TOVX Strong Buy
- Analyst Count
- LGMK 0
- TOVX 1
- Target Price
- LGMK N/A
- TOVX $6.00
- AVG Volume (30 Days)
- LGMK 355.3K
- TOVX 97.3K
- Earning Date
- LGMK 11-12-2024
- TOVX 11-12-2024
- Dividend Yield
- LGMK N/A
- TOVX N/A
- EPS Growth
- LGMK N/A
- TOVX N/A
- EPS
- LGMK N/A
- TOVX N/A
- Revenue
- LGMK $10,078,502.00
- TOVX N/A
- Revenue This Year
- LGMK $1.54
- TOVX N/A
- Revenue Next Year
- LGMK N/A
- TOVX N/A
- P/E Ratio
- LGMK N/A
- TOVX N/A
- Revenue Growth
- LGMK 4.44
- TOVX N/A
- 52 Week Low
- LGMK $1.53
- TOVX $1.14
- 52 Week High
- LGMK $32.48
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- LGMK 39.42
- TOVX 38.15
- Support Level
- LGMK $1.56
- TOVX $1.23
- Resistance Level
- LGMK $1.85
- TOVX $1.34
- Average True Range (ATR)
- LGMK 0.17
- TOVX 0.08
- MACD
- LGMK 0.00
- TOVX 0.01
- Stochastic Oscillator
- LGMK 6.20
- TOVX 12.50
About LGMK LogicMark Inc. (NV)
LogicMark Inc provides personal emergency response systems (PERS), health communications devices, and IoT technologies to create a connected care platform. Its devices give people the ability to receive care at home and confidence to age in place. The company incorporates two-way voice communication technology directly into its medical alert pendant and provides this life-saving technology at a price point that everyday consumers can afford.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.